{"entity":{"id":"nct06157827","kind":"trial","name":"A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma","aka":[],"tldr":"A phase 1/2 trial of Opamtistomig run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.","summary":"A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma is a phase 1/2 interventional study registered as NCT06157827 by Nanjing Leads Biolabs Co.,Ltd, with 178 participants planned, started 2023-12-08. Conditions recorded: Advanced Neuroendocrine Carcinoma. Interventions recorded: LBL-024 for Injection, Etoposide Injection, Carboplatin Injection, Atezolizumab injection and Cisplatin injection.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06157827","url":"https://clinicaltrials.gov/study/NCT06157827"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["neuroendocrine"],"sections":[],"technologies":[],"targets":[],"drugs":["opamtistomig"],"companies":["nanjing-leads-biolabs"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06157827","phase":"1/2","setting":"An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of LBL-024 Combined With Etoposide and Platinum in the First-line Treatment of Patients With Advanced Neuroendocrine Carcinoma (NEC)","sponsor":"Nanjing Leads Biolabs Co.,Ltd","enrolled":178,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06157827/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"}],"drug":[{"id":"opamtistomig","kind":"drug","name":"Opamtistomig","route":"/drugs/opamtistomig/"}],"company":[{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/"}]}}